Muscle is one of the most powerful and most underestimated predictors of long-term health. Beyond appearance or athletic performance, skeletal muscle plays a direct role in metabolic function, insulin sensitivity, cardiovascular health, cognitive protection, and lifespan. This playlist covers the science of muscle mass and strength — how they decline with age, why that decline matters clinically, and the evidence-based strategies for building and preserving them throughout life. Topics include resistance training, VO2 max, zone 2 cardio, visceral fat, body composition, and the physiological relationship between physical fitness and longevity.
Curated by: Doctor Alex (51 videos)
GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro and Zepbound are transforming obesity and type 2 diabetes treatment. Millions of people are losing weight rapidly — but there’s an important risk that almost nobody talks about: muscle loss, metabolic slowdown, and rapid weight regain when the drug stops. In this video I break down the Ozempic trap — what these drugs actually do inside your body, why a significant portion of the weight lost can come from lean muscle mass, and why that matters for long-term health, metabolism, and longevity. After nearly a decade working in emergency medicine, I’ve seen what actually destroys people’s health over time — heart disease, diabetes, metabolic dysfunction, and loss of muscle mass as people age. Muscle isn’t just cosmetic tissue. It is your metabolic engine, one of the strongest predictors of lifespan, insulin sensitivity, and resilience as you get older. The problem is that many people starting GLP-1 medications are never told how to protect their muscle, build healthy habits, or transition off safely. Without a plan, weight regain is extremely common — and when weight comes back, it often returns as fat rather than muscle. What you’ll learn: -How Ozempic, Wegovy, Mounjaro and other GLP-1 drugs actually work -Why rapid weight loss often includes muscle loss (lean mass) -Why muscle is critical for metabolism, blood sugar control and longevity -How calorie restriction on these drugs can accelerate muscle breakdown -The behavioural trap created by appetite suppression -Why weight regain after stopping GLP-1 drugs is so common -The health risks of weight cycling -The surprising social and behavioural consequences of these medications -The real root causes of obesity and metabolic disease -Natural ways to support GLP-1 hormone release through diet and lifestyle -How to come off Ozempic or Mounjaro safely -Who may actually benefit from staying on these drugs long term TIMESTAMPS 00:00 The Ozempic Trap Nobody Warned You About 01:20 What These Drugs Actually Do 02:40 The Body Composition Problem Nobody Talks About 06:44 The Behavioural Trap 07:34 Weight Cycling and Why It's Dangerous 09:44 The Social Cost 11:05 What The Root Cause Actually Is 16:17 How To Come Off Properly 19:23 Who Should Stay On 20:09 The Bottom Line References Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728 Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? http://ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676 Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis https://www.sciencedirect.com/science/article/abs/pii/S002604952400341X Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/ Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension https://pubmed.ncbi.nlm.nih.gov/35441470/ Body-Weight Fluctuation Was Associated With Increased Risk for Cardiovascular Disease, All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-Analysis https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00728/full Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1607141 #dralex #doctoralex #ozempic #mounjaro #wegovy #glp1 #weightlossdrugs #metabolichealth